RBC Capital Maintains Sector Perform on Aurinia Pharmaceuticals, Raises Price Target to $16

Benzinga Newsdesk www.benzinga.com Positive 89.9%

Neg 0% Neu 0% Pos 89.9%

RBC Capital analyst Douglas Miehm maintains Aurinia Pharmaceuticals (NASDAQ:AUPH) with a Sector Perform and raises the price target from $15 to $16.